Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sequential panitumumab + paclitaxel induction followed by radiotherapy + panitumumab in locally advanced head and neck cancer unsuitable for platinum
2012-003038-17Phase 2Active
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Oct 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and paclitaxel in head and neck cancer (HNC), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Objective response rate to induction treatment. Started Oct 2012; status: active.
02
Drugs
panitumumabpaclitaxel
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2012-003038-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003038-17.